{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:09:53Z","timestamp":1788458993955,"version":"build-2803163510"},"reference-count":41,"publisher":"Society of Nuclear Medicine","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.2967\/jnumed.119.237230","type":"journal-article","created":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T03:26:42Z","timestamp":1585970802000},"page":"1468-1475","source":"Crossref","is-referenced-by-count":13,"title":["<sup>177<\/sup>Lu-Lilotomab Satetraxetan Has the Potential to Counteract Resistance to Rituximab in Non-Hodgkin Lymphoma"],"prefix":"10.2967","volume":"61","author":[{"given":"Marion M.","family":"Malenge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Patzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne H.","family":"Ree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trond","family":"Stokke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Ceuppens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Middleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jostein","family":"Dahle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada H.V.","family":"Repetto-Llamazares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2020,4,3]]},"reference":[{"key":"2021051712152267000_61.10.1468.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21387"},{"key":"2021051712152267000_61.10.1468.2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"2021051712152267000_61.10.1468.3","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.150178"},{"key":"2021051712152267000_61.10.1468.4","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/1744666X.2019.1573672","article-title":"B-cell depleting immunotherapies: therapeutic opportunities and toxicities","volume":"15","author":"Del Bufalo","year":"2019","journal-title":"Expert Rev Clin Immunol."},{"key":"2021051712152267000_61.10.1468.5","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood."},{"key":"2021051712152267000_61.10.1468.6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3442"},{"key":"2021051712152267000_61.10.1468.7","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3816\/CLM.2000.n.015","article-title":"Rituximab therapy of B-cell neoplasms","volume":"1","author":"Petryk","year":"2000","journal-title":"Clin Lymphoma."},{"key":"2021051712152267000_61.10.1468.8","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","article-title":"Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin\u2019s lymphoma: safety and efficacy of re-treatment","volume":"18","author":"Davis","year":"2000","journal-title":"J Clin Oncol."},{"key":"2021051712152267000_61.10.1468.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2011.02.009"},{"key":"2021051712152267000_61.10.1468.10","first-page":"611","article-title":"Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression","volume":"5","author":"Davis","year":"1999","journal-title":"Clin Cancer Res."},{"key":"2021051712152267000_61.10.1468.11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.1.101"},{"key":"2021051712152267000_61.10.1468.12","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-011-9955-3"},{"key":"2021051712152267000_61.10.1468.13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-175208"},{"key":"2021051712152267000_61.10.1468.14","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1111\/j.1349-7006.2012.02307.x","article-title":"Comparison of CD20 expression in B-cell lymphoma between newly diagnosed, untreated cases and those after rituximab treatment","volume":"103","author":"Miyoshi","year":"2012","journal-title":"Cancer Sci."},{"key":"2021051712152267000_61.10.1468.15","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/cas.12307","article-title":"De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: molecular mechanisms and correlation with rituximab sensitivity","volume":"105","author":"Tokunaga","year":"2014","journal-title":"Cancer Sci."},{"key":"2021051712152267000_61.10.1468.16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1254"},{"key":"2021051712152267000_61.10.1468.17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-263533"},{"key":"2021051712152267000_61.10.1468.18","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.4.2600"},{"key":"2021051712152267000_61.10.1468.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2007.10.048"},{"key":"2021051712152267000_61.10.1468.20","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.1018"},{"key":"2021051712152267000_61.10.1468.21","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.79"},{"key":"2021051712152267000_61.10.1468.22","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00259-015-3175-6","article-title":"High treatment efficacy by dual targeting of Burkitt\u2019s lymphoma xenografted mice with a 177Lu-based CD22-specific radioimmunoconjugate and rituximab","volume":"43","author":"Weber","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2021051712152267000_61.10.1468.23","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/ejh.13139","article-title":"Combination of 177Lu-lilotomab with rituximab significantly improves the therapeutic outcome in preclinical models of non-Hodgkin\u2019s lymphoma","volume":"101","author":"Repetto-Llamazares","year":"2018","journal-title":"Eur J Haematol."},{"key":"2021051712152267000_61.10.1468.24","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/BF02982805","article-title":"Development of radioimmunotherapy for the treatment of non-Hodgkin\u2019s lymphoma","volume":"76","author":"Multani","year":"2002","journal-title":"Int J Hematol."},{"key":"2021051712152267000_61.10.1468.25","first-page":"85","article-title":"Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin\u2019s lymphoma","volume":"33","author":"Dahle","year":"2013","journal-title":"Anticancer Res."},{"key":"2021051712152267000_61.10.1468.26","doi-asserted-by":"crossref","first-page":"e0128816","DOI":"10.1371\/journal.pone.0128816","article-title":"Targeted cancer therapy with a novel anti-CD37 beta-particle emitting radioimmunoconjugate for treatment of non-Hodgkin lymphoma","volume":"10","author":"Repetto-Llamazares","year":"2015","journal-title":"PLoS One."},{"key":"2021051712152267000_61.10.1468.27","doi-asserted-by":"crossref","first-page":"e103070","DOI":"10.1371\/journal.pone.0103070","article-title":"177Lu-DOTA-HH1, a novel anti-CD37 radio-immunoconjugate: a study of toxicity in nude mice","volume":"9","author":"Repetto-Llamazares","year":"2014","journal-title":"PLoS One."},{"key":"2021051712152267000_61.10.1468.28","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/hon.2438_142","article-title":"Lymrit 37-01: updated results of a phase I\/II study of 177Lu-lilotomab satetraxetan, a novel CD37-targeted antibody-radionuclide-conjugate in relapsed NHL patients","volume":"35","author":"Kolstad","year":"2017","journal-title":"Hematol Oncol."},{"key":"2021051712152267000_61.10.1468.29","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(84)90435-6"},{"key":"2021051712152267000_61.10.1468.30","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.19873"},{"key":"2021051712152267000_61.10.1468.31","doi-asserted-by":"publisher","DOI":"10.1038\/74704"},{"key":"2021051712152267000_61.10.1468.32","first-page":"5866","article-title":"Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin\u2019s lymphoma severe combined immunodeficiency mouse model","volume":"9","author":"Hernandez-Ilizaliturri","year":"2003","journal-title":"Clin Cancer Res."},{"key":"2021051712152267000_61.10.1468.33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0066"},{"key":"2021051712152267000_61.10.1468.34","doi-asserted-by":"crossref","first-page":"6935","DOI":"10.1088\/0031-9155\/61\/19\/6935","article-title":"Realistic multi-cellular dosimetry for 177Lu-labelled antibodies: model and application","volume":"61","author":"Marcatili","year":"2016","journal-title":"Phys Med Biol."},{"key":"2021051712152267000_61.10.1468.35","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.207266"},{"key":"2021051712152267000_61.10.1468.36","doi-asserted-by":"crossref","first-page":"106","DOI":"10.2174\/18744710113069990018","article-title":"Targeted alpha therapy with 227Th-trastuzumab of intraperitoneal ovarian cancer in nude mice","volume":"6","author":"Heyerdahl","year":"2013","journal-title":"Curr Radiopharm."},{"key":"2021051712152267000_61.10.1468.37","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.12.6338"},{"key":"2021051712152267000_61.10.1468.38","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-0073"},{"key":"2021051712152267000_61.10.1468.39","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20052494"},{"key":"2021051712152267000_61.10.1468.40","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.107.043752"},{"key":"2021051712152267000_61.10.1468.41","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.neo.2017.06.001","article-title":"The antitumor activity of IMGN529, a CD37-targeting antibody-drug conjugate, is potentiated by rituximab in non-Hodgkin lymphoma models","volume":"19","author":"Hicks","year":"2017","journal-title":"Neoplasia."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.119.237230","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T20:51:51Z","timestamp":1621284711000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.119.237230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,3]]},"references-count":41,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10,1]]},"published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.2967\/jnumed.119.237230"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.119.237230","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,3]]}}}